Israel Englander’s Amicus Therapeutics FOLD Stock Holding History

Israel Englander’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-50,000	Closed	-$712K	–	5927
2025 Q4	$712K	Sell	50,000 -122,500	-71%	-$1.2M	﹤0.01%	4712
2025 Q3	$1.36M	Buy	+172,500	New	+$1.23M	﹤0.01%	4376
2021 Q1	–	Sell	-60,000	Closed	-$1.39M	–	6104
2020 Q4	$1.39M	Buy	+60,000	New	+$1.23M	﹤0.01%	3507
2015 Q2	–	Sell	-300,000	Closed	-$3.26M	–	3490
2015 Q1	$3.26M	Buy	+300,000	New	+$2.64M	0.01%	1656
2013 Q4	–	Sell	-200,000	Closed	-$464K	–	3543
2013 Q3	$464K	Sell	200,000 -200,000	-50%	-$502K	﹤0.01%	2599
2013 Q2	$932K	Buy	+400,000	New	+$1.23M	﹤0.01%	2001

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Israel Englander's FOLD Position: Q2 2026 in Review

Israel Englander sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 7,908,459 shares — an estimated $114M sold.

Israel Englander first reported a position in FOLD in Q2 2014 and held it in 39 quarters. The position peaked at $114M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

Israel Englander reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
Israel Englander sold 7,908,459 Amicus Therapeutics shares in Q2 2026, an estimated $114M.
Israel Englander first reported a position in Amicus Therapeutics in Q2 2014 and held it in 39 quarters.
Israel Englander's Amicus Therapeutics position peaked at $114M in Q1 2026.
2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.